Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Circulation

Volumn 135, Issue 25, 2017, Pages 2572-2574

  Virani, Salim S ^a,c,d   Akeroyd, Julia M ^b   Nambi, Vijay ^e   Heidenreich, Paul A ^b   Morris, Pamela B ^f   Nasir, Khurram ^g   Michos, Erin D ^h,i   Bittner, Vera A ^j   Petersen, Laura A ^k   Ballantyne, Christie M ^l  

^a Quality and Informatics Program   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Section of Health Services Research   (United States)

^d Cardiovascular Research Group   (United Kingdom)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^g VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j MIAMI CANCER INSTITUTE   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l University of Alabama at Birmingham   (United States)

more..

Author keywords

cardiovascular disease; cholesterol; lipids

Indexed keywords

ENZYME INHIBITOR; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; COST CONTROL; ENZYME INHIBITION; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; TITRIMETRY; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; COST; ECONOMICS; FEMALE; FOLLOW UP; GOVERNMENT; MALE; MIDDLE AGED; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; COSTS AND COST ANALYSIS; ELIGIBILITY DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASE 9; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 85020903486     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.028503     Document Type: Letter

References (5)

1. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017 376 1713 1722. doi: 10.1056/NEJMoa1615664.
2. Virani SS, Akeroyd JM, Ramsey DJ, Chan WJ, Frazier L, Nasir K, S Rajan S, Ballantyne CM, Petersen LA, Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: implications for care under the Affordable Care Act. Am Heart J 2016 181 74 82. doi: 10.1016/j.ahj.2016.07.020.
3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 suppl 2 S1 S45. doi: 10.1161/01.cir.0000437738.63853.7a.
4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 372 2387 2397. doi: 10.1056/NEJMoa1410489.
5. Department of Veterans Affairs National Acquisition Center (CCST) VA National Acquisition Center contract catalog search tool. https://www.va.gov/nac/Pharma/List?cboContractNumbers=&cboContractorNames=&txtCriteria1=evolocumab&TxtNDC=&txtPackage=&cboVAClass=&Sort=1&search=Search. Accessed March 19, 2017